X0206 3 2019-05-07 0 0001563880 Trevi Therapeutics, Inc. TRVI 0001659119 Aperture Venture Partners IV, L.P. 645 MADISON AVENUE, 20TH FLOOR NEW YORK NY 10022 0 0 1 0 0001775271 Aperture Ventures IV Management, LLC 645 MADISON AVENUE, 20TH FLOOR NEW YORK NY 10022 0 0 1 0 Series C Preferred Stock Common Stock 232892 D The Series C Preferred Stock and the dividends that have accrued thereon to date are convertible on a 9.5-for-one basis into the number of shares of Common Stock shown in Column 3 without payment of further consideration at the holder's election or automatically upon the closing of the Issuer's initial public offering. The number of shares of Common Stock into which the Series C Preferred Stock and accrued dividends thereon are convertible will increase on a daily basis without payment of further consideration as additional dividends accrue. The shares have no expiration date. Aperture Ventures IV Management, LLC, the general partner of Aperture Venture Partners IV, L.P., has sole voting and investment control with respect to shares of the Issuer's common stock held by Aperture Venture Partners IV, L.P. By: Aperture Venture Partners IV, L.P., By: Aperture Ventures IV Management, LLC, /s/ Eric Sillman, Member 2019-05-07 By: Aperture Ventures IV Management, LLC, /s/ Eric Sillman, Member 2019-05-07